RxSight/$RXST
1D1W1MYTD1Y5YMAX
Capital at risk
About RxSight
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.
- Ticker
- $RXST
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 461
- Headquarters
- Aliso Viejo, United States
- Website
- rxsight.com
RxSight Metrics
BasicAdvanced
$250M
-
-$1.14
1.13
-
Price and volume
Market cap
$250M
Beta
1.13
52-week high
$13.22
52-week low
$4.48
Average daily volume
846K
Financial strength
Current ratio
4.07
Quick ratio
3.572
Long term debt to equity
3.386
Total debt to equity
4.018
Interest coverage (TTM)
-3,936.64%
Profitability
EBITDA (TTM)
-51.575
Gross margin (TTM)
77.50%
Net profit margin (TTM)
-36.80%
Operating margin (TTM)
-43.20%
Effective tax rate (TTM)
-0.23%
Revenue per employee (TTM)
$280,000
Management effectiveness
Return on assets (TTM)
-10.41%
Return on equity (TTM)
-17.35%
Valuation
Price to revenue (TTM)
1.946
Price to book
0.95
Price to tangible book (TTM)
0.95
Price to free cash flow (TTM)
-9.138
Free cash flow yield (TTM)
-10.94%
Free cash flow per share (TTM)
-0.659
Growth
Revenue change (TTM)
-13.24%
Earnings per share change (TTM)
42.46%
3-year revenue growth (CAGR)
23.95%
3-year earnings per share growth (CAGR)
-16.45%
What the Analysts think about RxSight
Analyst ratings (Buy, Hold, Sell) for RxSight stock.
Analyst projections of the future price of RxSight stock.
RxSight Financial Performance
Revenues and expenses
RxSight Earnings Performance
Company profitability
Upcoming events
No upcoming events
RxSight News
AllArticlesVideos
Funds containing RxSight
Fund name | Fund size | $RXST weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.